A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
12/2006
12/28/2006	WO2006137595A1 Prophylactic/therapeutic agent for her2-expressing cancer
12/28/2006	WO2006137515A1 Therapeutic agent for cancer comprising polypeptide capable of inhibiting the function of synoviolin as active ingredient
12/28/2006	WO2006137514A1 Therapeutic agent for cancer comprising substance capable of inhibiting expression or function of synoviolin as active ingredient and screening method for the therapeutic agent for cancer
12/28/2006	WO2006137474A1 Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for producing the same
12/28/2006	WO2006137450A1 Crystal of phenylalanine derivative, process for producing the same and use thereof
12/28/2006	WO2006137435A1 Agonist to g protein-coupled receptor g2a and method of screening g2a activity controller
12/28/2006	WO2006137421A1 Agent for topical administration
12/28/2006	WO2006137398A1 Therapeutic agent for cancer
12/28/2006	WO2006137314A1 Radial brush
12/28/2006	WO2006137139A1 Method of isolating mangosteen and drug and health food containing the same
12/28/2006	WO2006137092A1 Fluorescent sulfonamide derivatives having carbonic anhydrase inhibiting activity and their use as theapeutic and diagnostic agents
12/28/2006	WO2006136823A1 Heterocyclic containing amines as kinase b inhibitors
12/28/2006	WO2006136821A1 Pharmaceutical compounds
12/28/2006	WO2006136606A2 Oxindole derivatives
12/28/2006	WO2006136564A1 Multidentate aza ligands able to complex metal ions and the use thereof in diagnostics and therapy
12/28/2006	WO2006136553A1 Imidazolinone and hydantoine derivatives as novel inhibitors of histone deacetylase
12/28/2006	WO2006136462A1 Benzofuranone derivatives as nonsteroidal progesterone receptor modulators
12/28/2006	WO2006136309A1 Cripowellins and synthetic derivatives thereof used as medicaments
12/28/2006	WO2006136305A1 SUBSTITUTED PYRR0LIDIN-2-0NES , PIPERIDIN-2-0NES AND ISOTHIAZOLIDINE-1, 1-DIOXIDES, THEIR USE AS KVl .5 POTASSIUM CHANNEL BLOCKERS AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM
12/28/2006	WO2006136304A1 Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them
12/28/2006	WO2006136232A1 Bicalutamide adsorbates, process for preparing same, and pharmaceutical compositions thereof
12/28/2006	WO2006136175A2 Pharmaceutical compositions comprising tacrolimus and a cyp3a4 inhibitor
12/28/2006	WO2006136008A1 Salicylic acid hydrazones as inhibitors of the erk mapkinase pathway and for the treatment of cancer
12/28/2006	WO2006135985A1 Therapeutic pro-apoptotic bh3-like molecules and methods for generating and/or selecting the same
12/28/2006	WO2006135973A1 Small molecule glycosaminoglycan mimetics
12/28/2006	WO2006135967A1 Modulation of egfr signalling by modulation of sphingosine kinase signalling
12/28/2006	WO2006135949A2 Tumour treatment with gliotoxin derivatives
12/28/2006	WO2006122274A3 Pharmaceutical formulations of rhodiola crenulata and methods of use thereof
12/28/2006	WO2006117461A3 Alkyl-, alkenyl- et alkynyl carbamate derivatives, the preparation and therapeutic use thereof
12/28/2006	WO2006116246A3 Method of treating cd30 positive lymphomas
12/28/2006	WO2006115633A3 Cyanine-chlorotoxin conjugate and method for intra-operative fluorescent visualization of cancer
12/28/2006	WO2006108670A3 Use of cd25 antibodies in immunotherapy
12/28/2006	WO2006105222A3 Carboxamide inhibitors of tgfb
12/28/2006	WO2006104417A3 Substance and method for treating neoplasms
12/28/2006	WO2006102112A3 Prokineticin 1 receptor
12/28/2006	WO2006099480A3 Stress proteins and peptides and methods of use thereof
12/28/2006	WO2006097617A3 Novel dihydropyrimidine derivatives and their use as anti-cancer agents
12/28/2006	WO2006091767A3 Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors
12/28/2006	WO2006089251A3 SYNERGISTIC EFFECT OF TGF-β BLOCKADE AND IMMUNOGENIC AGENTS ON TUMORS
12/28/2006	WO2006081251A3 Methods and compositions using 4-amino-2-(3-methyl-2,6-dioxopiperidin-3-yl)-isoindole-1-3-dione
12/28/2006	WO2006076620A3 Bendamustine pharmaceutical compositions for lyophilisation
12/28/2006	WO2006074397A3 Cripto binding molecules
12/28/2006	WO2006072625A3 Anti-kir combination treatments and methods
12/28/2006	WO2006060381A3 N-substituted benzimidazolyl c-kit inhibitors and combinatorial benzimidazole library
12/28/2006	WO2005103231A3 Dentritic cells charged with toxic substances in order to treat kidney cell carcinomas
12/28/2006	WO2005090406A3 Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
12/28/2006	WO2005084712A3 Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment
12/28/2006	WO2005054295A3 Therapeutic and diagnostic anti-hsp 70 antibodies
12/28/2006	US20060294604 Model for studying the role of genes in tumor resistance to chemotherapy
12/28/2006	US20060293543 Isolation of lutein from alfalfa
12/28/2006	US20060293527 Analogs of epothilone
12/28/2006	US20060293391 Use of 15-deoxyspergualin for the treatment of hyperreactive inflammatory diseases and autoimmune diseases
12/28/2006	US20060293390 Diflunisal for the treatment of cancer
12/28/2006	US20060293348 CSBP/p38 kinase inhibitor; antiinflammatory agent; inflammatory bowel disease; tuberculosis, atherosclerosis, muscle degeneration, cachexia, psoriatic arthritis, rheumatoid arthritis; 8-(2,4,6-trifluorophenyl)-4-(2,4-difluorophenyl)-2-(2-hydroxy-1-hydroxymethylethylamino)-8H-pyridio[2,3]pyrimidin-7-one
12/28/2006	US20060293347 Pharmaceutically active compounds
12/28/2006	US20060293340 2-Aminopyrimidine derivatives as raf kinase inhibitors
12/28/2006	US20060293333 Therapeutic amides
12/28/2006	US20060293326 2-Heteroaryl-imidazotriazinones and their use in the treatment of inflammatory or immune diseases
12/28/2006	US20060293323 Therapeutic Combinations of erb B Kinase Inhibitors and Antineoplastic Therapies
12/28/2006	US20060293322 For therapy of lung and breast cancer
12/28/2006	US20060293291 bone formation is desired, such as osteoporosis, as well as autoimmune diseases such as multiple sclerosis, diabetes mellitus and lupus; exhibit pronounced activity in arresting the proliferation of undifferentiated cells; 2-[(3'-methoxymethoxy)propylidene]-19-nor-1 alpha ,25-(OH)2,D3
12/28/2006	US20060293275 Hgf production accelerator containing heparin-like oligosaccharide
12/28/2006	US20060293254 Podophyllotoxin
12/28/2006	US20060293252 such as 3-(4-Methoxy-phenyl)-1-[3-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-thiophen-2-yl]-propan-1-one; for use as antidiabetics
12/28/2006	US20060293249 Porphyrin derivatives
12/28/2006	US20060293242 Transporting of taxoid derivatives through the blood brain barrier
12/28/2006	US20060293226 Medicament and use thereof for tumor therapy
12/28/2006	US20060292673 For degradation of glycosaminoglycans; inhibiting angiogenesis and cellular proliferation; treating cancer, neurodegenerative disease, atherosclerosis and microbial infection
12/28/2006	US20060292655 2-O sulfatase compositions and methods of analyzing therewith
12/28/2006	US20060292648 Screening for target that disrupts interaction between human osteopontin (OPN) and an alpha 4 integrin; inflammatory diseases
12/28/2006	US20060292644 Novel tumor-associated marker
12/28/2006	US20060292593 Nucleotide sequences coding B7 immune response regulatory protein selectively expressed on dendritic cells for use as therapeutic tool in targeting viral and tumor cell for destruction
12/28/2006	US20060292218 A cytocidyl mixture of alpha-ketoglutaric acid and salts, N-acetyl-seleno-L-methionine, N-acetyl-L-methionine, and 5-hydroxymethylfurfural that is capable of forming azomethine; angiogenesis inhibition; cancerous tumors of the breast, uterus, esophagus, bladder, lung
12/28/2006	US20060292204 5,7,3',4'-Tetrahydroxy-5'-C-geranylflavanone (isonymphaeol-B), isolated from an Okinawa propolis; microbiocide, antitumor agent, food, beverage and cosmetic preservative; antioxidant food supplement
12/28/2006	US20060292139 Eukaryotic host cell containing a nucleic acid sequence coding for a bivalent or a multivalent glycosylated compound having two or more single polypeptide chain antigen binding regions linked to a prodrug-activating enzyme; transgenic nonhuman mammal having the sequence
12/28/2006	US20060292136 Cytotoxic factors for modulating cell death
12/28/2006	US20060292133 Use of lactobacillus salivarius
12/28/2006	US20060292131 Chondrocyte Therapeutic Delivery System
12/28/2006	US20060292130 2-O sulfatase nucleic acid compositions
12/28/2006	US20060292116 Reduced vasopermeability activity and similar binding affinity for an IL-2 receptor compared to its wildtype form; immunostimulants; immuotherapy; anticarcinogenic agents; renal cell cancer, melanoma; chemotherapy and/or radiation therapy; viricides; human immunodeficiency virus; autoimmune disorders
12/28/2006	US20060292112 Dendrimer-photosensitizer complexes for medical applications
12/28/2006	DE102005053679A1 Use of floroquinolones for producing medicament to treat and/or prevent e.g. immunosuppresion, viral and bacterial infections, respiratory tract diseases, digestive tract diseases, and influenza diseases
12/28/2006	DE102005029126A1 New cripowellin derivatives useful in the preparation of medicament for the treatment of cancer or other proliferative diseases
12/28/2006	DE102005028845A1 New substituted pyrrolidin-2-ones, piperidin-2-ones and isothiazolidine-1,1-dioxides useful for treating e.g. dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, breast cancer and heart failure
12/28/2006	DE102005027478A1 Active substance, useful for treating tumors in renal tissue, comprises a peptide toxin, a substance, homeopathic Tarantula D4 in sodium chloride solution and saturated solution of poison cocktail of spiders of Loxoscele laeta
12/28/2006	CA2850323A1 Methods and compositions involving mirna and mirna inhibitor molecules
12/28/2006	CA2680945A1 Anti-pdgfralpha antibodies
12/28/2006	CA2678008A1 Methods of treating a secondary bone tumor with anti-pdgfralpha antibodies
12/28/2006	CA2613480A1 Therapeutic pro-apoptotic bh3-like molecules and methods for generating and/or selecting the same
12/28/2006	CA2613249A1 Crystals of phenylalanine derivatives, production method thereof and use thereof
12/28/2006	CA2613001A1 Quinoline 3 -sulfonate esters as nk3 receptor modulators
12/28/2006	CA2612913A1 Cripowellins and synthetic derivatives thereof used as medicaments
12/28/2006	CA2612829A1 Pharmaceutical compositions comprising tacrolimus and a cyp3a4 inhibitor
12/28/2006	CA2612770A1 Tumour treatment with gliotoxin derivatives
12/28/2006	CA2612640A1 Modulation of egfr signalling by modulation of sphingosine kinase signalling
12/28/2006	CA2612451A1 Oxindole derivatives
12/28/2006	CA2611900A1 Benzofuranone derivatives as nonsteroidal progesterone receptor modulators
12/28/2006	CA2611785A1 Use of hif 1alfa modulators for treatment of cancer
12/28/2006	CA2611712A1 Combretastatin analogs with tubulin binding activity
12/28/2006	CA2611474A1 Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor

1 ... 1120 1121 1122 1123 1124 1125 1126 1127 1128 1129 1130 1131 1132 1133 1134 1135 1136 1137 1138 1139 1140 ... 2211